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P. De Rango
Unit of Vascular Surgery, Hospital S.M. Misericordia, University of Perugia, Perugia, ItalyThe expansion of endovascular repair has contributed to
decreased mortality rates in acute aortic syndromes, yet
the outcome of patients with descending thoracic aortic
ruptures remains unsatisfactory. The development of se-
vere, early, and late complications that are poorly
addressed, as well as the lack of standardized and
well known management, remain substantial concerns,
increasing the overall fatality related to the disease. In
depth understanding of patients with aortic rupture, usu-
ally only sporadically treated, can be provided by more
consistent numbers pooled from registries. In this issue of
the European Journal of Vascular and Endovascular Sur-
gery, data from a multicenter experience provide useful
insights on the management of 56 patient with hemo-
thorax, a common but undeﬁned complication after
descending thoracic ruptures treated by thoracic endo-
vascular repair (TEVAR).1 The authors used an aggressive
approach, draining 37.5% of the patients, with comparable
rates in those with traumatic and non-traumatic thoracic
aortic rupture (48% vs. 33%; p ¼ .84), despite the worse
respiratory conditions, due to the traumatic incident, in
the former group of younger patients. Both, chest tube
and surgical evacuation, were applied, even though the
ﬁrst strategy was preferred. This aggressive approach
allowed for the lack of any effect of respiratory compli-
cations on mortality and for a low in hospital mortality rate
(12.5%). Nevertheless, the lack of a comparison group with
a less aggressive drainage strategy and the non-random
allocation of treatment do not allow the derivation of
strong recommendations on the best management of
hemothorax in aortic ruptures. It cannot be excluded that
a more conservative treatment of hemothorax, as used by
others in diverse patient settings,2 would have been
detrimental or could have allowed similar survival.
Despite the low in hospital mortality, almost half the
patients treated by TEVAR for acute thoracic rupture and
hemothorax in this multicenter registry died within 5 years:
the survival estimates at 5 years being 61%. This ﬁnding mayDOI of original article: http://dx.doi.org/10.1016/j.ejvs.2015.07.039
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whatever the reason for thoracic rupture. Of relevance, late
mortality was mainly related to cardiac ischemic events.
Thereby, a further lesson from this multicenter experience
of acute aortic treatment is the need to address globally the
cardiovascular risk of patients after resolution of the hy-
peracute phase: most of the non-traumatic aortic ruptures
were indeed from patients with atherosclerotic thoracic
aneurysms and high cardiovascular risk burden. Patients
were old and obese, with a frequent history of cardiac
disease, diabetes, and hypertension.1 From this multicenter
study we do not know if, or how many of these patients
after acute thoracic rupture, were maintained on best
medical treatment and were following the recommended
goal directed lifestyles to prevent cardiovascular disease
and mortality. Despite the demonstrated beneﬁt and the
extensive application of medical therapy (e.g., statins, an-
tihypertensives, antiplatelets, etc.)3 in cardiology patients,
there is still a lack of a systematic and aggressive medical
approach for many vascular patients, especially when sur-
viving an acute catastrophe such as acute aortic rupture.
In summary, there is a need to standardize the approach
to patients with acute aortic events to decrease the impact
of major pulmonary and cardiac complications on the high
(early and late) fatality rates related to the disease, and
further studies should focus on this. While the aggressive
use of hemothorax drainage, as suggested by the recent
multicenter study, is still unsupported by solid widespread
evidence, following recommended cardiovascular goals is a
well demonstrated and useful adjunct that can likely
improve the survival of patients with acute aortic
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